Boston Scientific (CHIX:BSXD) Cyclically Adjusted Revenue per Share: €0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:BSXD Boston Scientific Corp CHIX:BSXD
67 GF Score
Price €37.64
GF Value €91.85
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Boston Scientific Cyclically Adjusted Revenue per Share?

Boston Scientific CHIX:BSXD 67 Cyclically Adjusted Revenue per Share is €0.00 as of Mar. 2026. GuruFocus rates CHIX:BSXD with a GF Score™ of 67/100 and a GF Value™ of €91.85 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Boston Scientific's adjusted revenue per share for the three months ended in Mar. 2026 was €3.010. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Boston Scientific's average Cyclically Adjusted Revenue Growth Rate was 9.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 5.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Boston Scientific was 16.80% per year. The lowest was -2.90% per year. And the median was 5.70% per year.

As of today (2026-07-24), Boston Scientific's current stock price is €37.64. Boston Scientific's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.00. Boston Scientific's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Boston Scientific was 11.69. The lowest was 3.51. And the median was 6.07.


Boston Scientific  (CHIX:BSXd) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Boston Scientific was 11.69. The lowest was 3.51. And the median was 6.07.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Boston Scientific Cyclically Adjusted Revenue per Share Related Terms


Boston Scientific Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Boston Scientific's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boston Scientific Cyclically Adjusted Revenue per Share Chart

Boston Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Boston Scientific Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CHIX:BSXD vs EW, GEHC, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Boston Scientific's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boston Scientific Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Boston Scientific's Cyclically Adjusted PS Ratio falls into.


CHIX:BSXD
67GF Score
Boston Scientific Corp CHIX:BSXD
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boston Scientific Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Boston Scientific's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.01/330.2130*330.2130
=3.010

Current CPI (Mar. 2026) = 330.2130.

Boston Scientific Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.394 241.018 1.910
201609 1.359 241.428 1.859
201612 1.501 241.432 2.053
201703 1.453 243.801 1.968
201706 1.444 244.955 1.947
201709 1.337 246.819 1.789
201712 1.458 246.524 1.953
201803 1.381 249.554 1.827
201806 1.524 251.989 1.997
201809 1.461 252.439 1.911
201812 1.601 251.233 2.104
201903 1.567 254.202 2.036
201906 1.653 256.143 2.131
201909 1.741 256.759 2.239
201912 1.849 256.974 2.376
202003 1.628 258.115 2.083
202006 1.261 257.797 1.615
202009 1.578 260.280 2.002
202012 1.560 260.474 1.978
202103 1.616 264.877 2.015
202106 1.783 271.696 2.167
202109 1.736 274.310 2.090
202112 1.927 278.802 2.282
202203 1.910 287.504 2.194
202206 2.134 296.311 2.378
202209 2.223 296.808 2.473
202212 2.121 296.797 2.360
202303 2.189 301.836 2.395
202306 2.281 305.109 2.469
202309 2.241 307.789 2.404
202312 2.313 306.746 2.490
202403 2.394 312.332 2.531
202406 2.579 314.175 2.711
202409 2.550 315.301 2.671
202412 2.923 315.605 3.058
202503 2.889 319.799 2.983
202506 2.938 322.561 3.008
202509 2.886 324.800 2.934
202512 3.018 324.054 3.075
202603 3.010 330.213 3.010

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.00 mean?
Boston Scientific (CHIX:BSXD) has a Cyclically Adjusted Revenue per Share of €0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Boston Scientific and its competitors.
Is Boston Scientific's Cyclically Adjusted Revenue per Share too high?
Boston Scientific's current Cyclically Adjusted Revenue per Share is €0.00. Overall, Boston Scientific has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's Cyclically Adjusted Revenue per Share compare to EW and GEHC?
Boston Scientific's Cyclically Adjusted Revenue per Share of €0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Boston Scientific and its competitors. Boston Scientific's current Cyclically Adjusted Revenue per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (CHIX:BSXD) is currently considered Significantly Undervalued. The stock's GF Value™ is €91.85, compared to a current price of €37.64 — trading 59% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.00. Boston Scientific's overall GF Score™ is 67/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Boston Scientific (CHIX:BSXD), the current Cyclically Adjusted Revenue per Share is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Boston Scientific (CHIX:BSXD) Overvalued in 2026?

Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued. The current stock price of €37.64 is trading 59% below its estimated GF Value™ of €91.85. GuruFocus considers Boston Scientific to be Significantly Undervalued.

Key valuation signals for CHIX:BSXD:

  • Cyclically Adjusted Revenue per Share: €0.00
  • GF Value™: €91.85 vs. price of €37.64 (59% below fair value)
  • GF Score™: 67/100 with 1 warning sign

No single metric tells the full story. See the CHIX:BSXD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Boston Scientific Business Description

Address 300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
67GF Score

Get the complete analysis for CHIX:BSXD

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€37.64
Price
€91.85
GF Value